Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs zoledronic acid for prevention of skeletal-related events in advanced breast cancer with bone metastases
2006-000339-93Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in breast cancer and bone metastases (2 arms), sponsored by Amgen. Primary endpoint: Time to first on-study skeletal-related event (non-inferiority). Started Apr 2006; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2006-000339-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000339-93.